Clinical Administration Protocols
Evidence-based guidelines for the initiation and escalation of GLP-1 and dual-agonist metabolic therapies. These protocols are derived from the latest clinical trial data for 2026.
Dose Titration Strategy
The primary objective of a structured titration schedule is to maximize metabolic efficiency while minimizing gastrointestinal sensitivity. Standard clinical practice follows a "Start Low, Go Slow" methodology.
Standard 12-Week Escalation Phase
| Phase | Duration | Standard Tirzepatide Dosage | Objective |
|---|---|---|---|
| Initiation | Weeks 1-4 | 2.5 mg Weekly | Metabolic Conditioning |
| Intermediate | Weeks 5-8 | 5.0 mg Weekly | Active Glycemic Control |
| Therapeutic | Weeks 9-12 | 7.5 mg - 10 mg | Optimal Weight Management |
Administration Best Practices
- Subcutaneous Delivery: Injections should be administered in the abdomen, thigh, or upper arm, rotating sites weekly to maintain tissue health.
- Temporal Consistency: It is recommended to administer weight loss injections on the same day each week to maintain stable plasma concentrations.
- Oral Alternatives: When utilizing oral semaglutide options, strict fasting (at least 30 minutes post-dose) is required to ensure optimal peptide absorption.
Clinical Monitoring Markers
Comprehensive support involves regular tracking of the following markers:
- HbA1c levels: To monitor long-term glycemic stability.
- Renal Function (eGFR): Essential for safety, particularly if gastrointestinal transit slows significantly.
- Body Composition Analysis: Utilizing DEXA scans to ensure that weight loss is derived from adipose tissue rather than lean muscle mass.